Bayer, Onyx cancer drug shows modest improvement in survival
A colorectal cancer drug under development by Bayer HealthCare modestly improved overall survival in some of the sickest patients in a late-stage trial, partner Onyx Pharmaceuticals Inc.?
The median overall survival of patients on experimental regorafenib was 6.4 months. That compares to five months for patients who were given a placebo.
Onyx called the finding, released at the American Society of Clinical Oncology's gastrointestinal cancer meeting in San Francisco, statistically significant. But critics appeared less than wowed by the small improvement.
The companies also said the 760-patient study showed that patients on regorafenib had a better median progression-free survival rate than those on placebo -- 1.9 months versus 1.7 months -- and a better disease control rate.
Source: http://feeds.bizjournals.com/~r/vertical_38/~3/f6CACCRVFvE/bayer-onyx-cancer-drug-shows-modest.html
sandusky interview with bob costas live oak mark kelly mark kelly jeff goldblum uc berkeley ohio state basketball